Clinical trial
Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock
NCT03643367 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock
- Lead sponsor
- University of Zurich
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 31, 2026
- Completion date
- November 30, 2027
- Enrollment
- 153 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.